Source: Eur Respir J 2004; 24: 367-370
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Hallstrand T.S., Ochs H.D., Zhu Q., Liles W.C.. Inhaled IFN-γ for persistent nontuberculous mycobacterial pulmonary disease due to functional IFN-γ deficiency. Eur Respir J 2004; 24: 367-370

Member's Comments

No comment yet.

Related content which might interest you: Re-activation of bovine tuberculosis in a patient treated with infliximab Source: Eur Respir J 2008; 32: 229-231 Year: 2008 Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis Source: Eur Respir J 2003; 21: 483-488 Year: 2003 Pulmonary infections in patients receiving treatment of tumor necrosis factor alpha antagonists Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015 Should isoniazid prophylaxis be prescribed to the patients under tumor necrosis factor-alpha antagonists independent of tuberculin skin test? Source: International Congress 2015 – Screening strategies in TB Year: 2015 Interferon-γ therapy in two patients with progressive chronic pulmonary aspergillosis Source: Eur Respir J 2006; 27: 1307-1310 Year: 2006 Isoniazid protection and risk of tuberculosis in patients who used anti tumor necrosis factor-alpha treatment Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease Year: 2007 Miliary tuberculosis during treatment with anti TNF alpha - a report of four cases Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management II Year: 2013 Mycolic acid from mycobacterium tuberculosis suppresses experimental asthma by triggering the local induction of regulatory T cells Source: Annual Congress 2006 - Cellular immunology in asthma pathogenesis Year: 2006 Interferon gamma (IFN?) pathway deficiency and severe NTM disease Source: Virtual Congress 2021 – Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease Year: 2021 Variability of sputum inflammatory mediators in COPD and ?1-antitrypsin deficiency}, Source: Eur Respir J 2012; 40: 561-569 Year: 2012 Utility of mycobacterium tuberculosis Rv0081-specific host gene expression to distinguish latent infection from active tuberculosis disease Source: International Congress 2016 – Active and latent tuberculosis: biomarkers Year: 2016 The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement Source: Eur Respir J 2010; 36: 1185-1206 Year: 2010 Implication of leptin, tumor necrosis factor-alpha, interleukin-1 and interleukin-6 in the pathogenesis of wasting in tuberculosis Source: Annual Congress 2006 - Immunology of tuberculosis and diagnosis of tuberculosis infection Year: 2006 Diagnosing latent tuberculosis in immunocompromised patients measuring blood IP-10 production capacity: An analysis of chronic renal faulire patients Source: International Congress 2015 – Screening strategies in TB Year: 2015 Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis? Source: Eur Respir J 2003 Dec 01;22(6):906-911 Year: 2003 Clinical relevance of Mycobacterium simiae in pulmonary samples Source: Eur Respir J 2008; 31: 106-109 Year: 2008 Is low body fat responsible for increased susceptibility to nontuberculous mycobacterial lung disease? Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013 Alveolar macrophages are the main source for tumour necrosis factor-α in patients with sarcoidosis Source: Eur Respir J 2003; 21: 421-428 Year: 2003 Could pulmonary tuberculosis present without any inflammatory response? Source: Eur Respir J 2005; 26: Suppl. 49, 420s Year: 2005 Silica exposure, silicosis, autoimmune diseases, tuberculosis and nontuberculous pulmonary mycobacterial disease Source: International Congress 2016 – Occupational epidemiology Year: 2016